PT - JOURNAL ARTICLE AU - Action to beat coronavirus/Action pour battre le coronavirus (Ab-C) Study Investigators AU - Prabhat Jha TI - COVID Seroprevalence, Symptoms and Mortality During the First Wave of SARS-CoV-2 in Canada AID - 10.1101/2021.03.04.21252540 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.04.21252540 4099 - http://medrxiv.org/content/early/2021/03/05/2021.03.04.21252540.short 4100 - http://medrxiv.org/content/early/2021/03/05/2021.03.04.21252540.full AB - Background Efforts to stem Canada’s SARS-CoV-2 pandemic can benefit from direct understanding of the prevalence, infection fatality rates (IFRs), and information on asymptomatic infection.Methods We surveyed a representative sample of 19,994 adult Canadians about COVID symptoms and analyzed IgG antibodies against SARS-CoV-2 from self-collected dried blood spots (DBS) in 8,967 adults. A sensitive and specific chemiluminescence ELISA detected IgG to the spike trimer. We compared seroprevalence to deaths to establish IFRs and used mortality data to estimate infection levels in nursing home residents.Results The best estimate (high specificity) of adult seroprevalence nationally is 1.7%, but as high as 3.5% (high sensitivity) depending on assay cut-offs. The highest prevalence was in Ontario (2.4-3.9%) and in younger adults aged 18-39 years (2.5-4.4%). Based on mortality, we estimated 13-17% of nursing home residents became infected. The first viral wave infected 0.54-1.08 million adult Canadians, half of whom were <40 years old. The IFR outside nursing homes was 0.20-0.40%, but the COVID mortality rate in nursing home residents was >70 times higher than that in comparably-aged adults living in the community. Seropositivity correlated with COVID symptoms, particularly during March. Asymptomatic adults constituted about a quarter of definite seropositives, with a greater proportion in the elderly.Interpretation Canada had relatively low infection prevalence and low IFRs in the community, but not in nursing homes, during the first viral wave. Self-collected DBS for antibody testing is a practicable strategy to monitor the ongoing second viral wave and, eventually, vaccine-induced immunity among Canadian adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was funded by an unrestricted grant from Pfizer Global Medical Grants, Unity Health Foundation and the Canadian COVID-19 Immunity Task Force. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Unity Health Toronto Ethics Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request and subject to approval from Unity Health Toronto Ethics Review Board and the Canadian COVID-19 Immunity Task Force.